<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell Mol Life Sci</journal-id><journal-id journal-id-type="iso-abbrev">Cell Mol Life Sci</journal-id><journal-id journal-id-type="pmc-domain-id">4579</journal-id><journal-id journal-id-type="pmc-domain">cmls</journal-id><journal-title-group><journal-title>Cellular and Molecular Life Sciences: CMLS</journal-title></journal-title-group><issn pub-type="ppub">1420-682X</issn><issn pub-type="epub">1420-9071</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11115711</article-id><article-id pub-id-type="pmcid-ver">PMC11115711.1</article-id><article-id pub-id-type="pmcaid">11115711</article-id><article-id pub-id-type="pmcaiid">11115711</article-id><article-id pub-id-type="pmid">20717836</article-id><article-id pub-id-type="doi">10.1007/s00018-010-0491-7</article-id><article-id pub-id-type="publisher-id">491</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Multi-Author Review</subject></subj-group></article-categories><title-group><article-title>Targeting <italic toggle="yes">O</italic>
<sup>6</sup>-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Kaina</surname><given-names initials="B">Bernd</given-names></name><address><phone>+49-6131-179217</phone><fax>+49-6131-230506</fax><email>kaina@uni-mainz.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Margison</surname><given-names initials="GP">Geoffrey P.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Christmann</surname><given-names initials="M">Markus</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.410607.4</institution-id><institution>Institute of Toxicology, </institution><institution>University Medical Center, </institution></institution-wrap>Obere Zahlbacher Str. 67, 55131 Mainz, Germany </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.5379.8</institution-id><institution-id institution-id-type="ISNI">0000000121662407</institution-id><institution>Cancer Research-UK Carcinogenesis Group, Paterson Institute for Cancer Research, </institution><institution>University of Manchester, </institution></institution-wrap>Manchester, M20 4BX UK </aff></contrib-group><pub-date pub-type="epub"><day>18</day><month>8</month><year>2010</year></pub-date><pub-date pub-type="collection"><month>11</month><year>2010</year></pub-date><volume>67</volume><issue>21</issue><issue-id pub-id-type="pmc-issue-id">463161</issue-id><fpage>3663</fpage><lpage>3681</lpage><history><date date-type="received"><day>28</day><month>7</month><year>2010</year></date><date date-type="accepted"><day>28</day><month>7</month><year>2010</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>08</month><year>2010</year></date></event><event event-type="pmc-live"><date><day>24</day><month>05</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-05-24 18:25:14.580"><day>24</day><month>05</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; Springer Basel AG 2010</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="18_2010_Article_491.pdf"/><abstract id="Abs1"><p><italic toggle="yes">O</italic><sup>6</sup>-methylguanine-DNA methyltransferase (MGMT) repairs the cancer chemotherapy-relevant DNA adducts, <italic toggle="yes">O</italic><sup>6</sup>-methylguanine and <italic toggle="yes">O</italic><sup>6</sup>-chloroethylguanine, induced by methylating and chloroethylating anticancer drugs, respectively. These adducts are cytotoxic, and given the overwhelming evidence that MGMT is a key factor in resistance, strategies for inactivating MGMT have been pursued. A number of drugs have been shown to inactivate MGMT in cells, human tumour models and cancer patients, and <italic toggle="yes">O</italic><sup>6</sup>-benzylguanine and <italic toggle="yes">O</italic><sup>6</sup>-[4-bromothenyl]guanine have been used in clinical trials. While these agents show no side effects per se, they also inactivate MGMT in normal tissues and hence exacerbate the toxic side effects of the alkylating drugs, requiring dose reduction. This might explain why, in any of the reported trials, the outcome has not been improved by their inclusion. It is, however, anticipated that, with the availability of tumour targeting strategies and hematopoetic stem cell protection, MGMT inactivators hold promise for enhancing the effectiveness of alkylating agent chemotherapy.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>MGMT</kwd><kwd>Alkyltransferase</kwd><kwd>Glioblastoma</kwd><kwd>Melanoma</kwd><kwd>Drug resistance</kwd><kwd>Repair inhibitors</kwd><kwd>Inhibitor targeting</kwd><kwd><italic toggle="yes">O</italic><sup>6</sup>-benzylguanine</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Basel AG 2010</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>